UPClytics
EnglishDeutsch
Sign inSign up
View all cases

UPC APP 43687/2024

Jul 29, 2024·EP3167888: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Case details
Status
Case Closed
Action
Generic
Category
Other Procedural
Parties
Claimants
Reps: Tilman Mueller-Stoy
Respondents
Reps: Elena Hennecke
Division
Hamburg LD
Judges
Technology
Organic Chemistry
Language
English
Documents
Document titleDatePublic
action.phaseChange.caseClose2025-12-05Not public
action.issueOrder.order2025-12-02Not public
Order2025-12-02Not public
Cover sheet2025-11-26Not public
Further pleadings2025-11-26Not public
Further pleadings2025-11-26Not public
Receipt2025-11-26Not public
Cover sheet2025-11-25Not public
Other document Claimant2025-11-25Not public
Receipt2025-11-25Not public
Cover sheet2025-11-25Not public
Application document Claimant2025-11-25Not public
Receipt2025-11-25Not public
Receipt2025-09-11Not public
Brief_re_cost_application_first_instance_Amgen2025-09-11Not public
Receipt2025-08-20Not public
Rule 262.2-Application2025-08-19Not public
Comments2025-08-19Not public
Comments2025-08-19Not public
Anhoerung2025-08-05Not public
Outcome of the Order2025-08-05Not public
Order with grounds2025-08-05Public
Order with grounds2025-08-05Not public
Order with grounds2025-08-05Public
Order with grounds2025-08-05Not public
Comments2025-08-04Not public
Anhoerung2025-07-29Not public
Receipt2025-07-15Not public
Confidentiality_requests_EN_signed2025-07-14Not public
Confidentiality_requests_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Costs_awarded_reply_CONFIDENTIAL_EN_signed2025-07-14Not public
Anhoerung2025-07-02Not public
Comments2024-09-09Not public
Submission2024-09-09Not public
Submission2024-09-09Not public
Submission2024-09-09Not public
Submission2024-09-09Not public
Submission2024-09-09Not public
Submission2024-09-09Not public
Submission2024-09-09Not public
Submission2024-09-09Not public
Submission2024-09-09Not public
anhoerung kosten2024-08-12Not public
Receipt2024-07-29Not public
Application2024-07-26Not public
Amgen Technology (Ireland) Unlimited Comp… v Alexion Pharmaceuticals, Inc. — UPC APP 43687/2024 | UPClytics